Therapeutic misconceptions are common among patients even after they sign informed consent statements asserting that they fully comprehend the pros and cons of clinical trials, said Boston researchers in a study appearing in the November 24 issue of The Lancet.
In the study, which was conducted at Dana-Farber Cancer Institute, Massachusetts General Hospital, and Brigham and Women's Hospital, 205 adult cancer patients who had recently enrolled in phase 1, 2, and 3 clinical trials in Boston completed questionnaires about their understanding of the studies.
Mitka M. Not-so-Informed Consent. JAMA. 2001;286(24):3071. doi:10.1001/jama.286.24.3071-JQU10011-5-1